Acute traumatic extremity ischemia remains a significant cause of limb loss and late limb dysfunction on the battlefield. Even with restoration of blood flow, the period of ischemia initiates a metabolic cascade that will lead to severe dysfunction of the leg and loss of the extremity in some cases. Even in cases when the blood flow is restored, additional injury to the muscle occurs, which is known as ischemia-reperfusion injury. Pyruvate is a naturally occurring metabolite that offers the promise of controlling the metabolic cascade of ischemia-reperfusion injury. This study will test whether ethyl pyruvate is protective in a pig model of limb ischemia with reperfusion. Ethyl pyruvate is one of the few agents that has shown positive results in a rodent model when administered in a clinically relevant post-ischemia protocol, e.g. the agent is effective even when administered after the leg has become ischemic. Given that small animal studies have been performed and indicate that it will likely be useful for human applications, we will combine the use of Ethyl Pyruvate with a model of perfusion-reperfusion injury in a large animal model that better simulates the way the human body responds to treatment of this important injury process.